Vanguard Group Inc. Purchases 1,333,421 Shares of Arcus Biosciences, Inc. $RCUS

Vanguard Group Inc. increased its position in Arcus Biosciences, Inc. (NYSE:RCUS) by 20.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,962,874 shares of the company’s stock after purchasing an additional 1,333,421 shares during the quarter. Vanguard Group Inc. owned approximately 0.07% of Arcus Biosciences worth $189,755,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC lifted its position in Arcus Biosciences by 17.5% in the fourth quarter. GAMMA Investing LLC now owns 3,230 shares of the company’s stock worth $77,000 after purchasing an additional 482 shares during the period. Amalgamated Bank lifted its position in Arcus Biosciences by 3.9% in the third quarter. Amalgamated Bank now owns 19,533 shares of the company’s stock worth $266,000 after purchasing an additional 736 shares during the period. Creative Planning lifted its position in Arcus Biosciences by 2.7% in the third quarter. Creative Planning now owns 29,629 shares of the company’s stock worth $403,000 after purchasing an additional 771 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Arcus Biosciences by 9.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 18,873 shares of the company’s stock worth $440,000 after purchasing an additional 1,649 shares during the period. Finally, Yousif Capital Management LLC lifted its position in Arcus Biosciences by 7.8% in the fourth quarter. Yousif Capital Management LLC now owns 23,207 shares of the company’s stock worth $509,000 after purchasing an additional 1,674 shares during the period. 92.89% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on RCUS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Monday, April 20th. Wells Fargo & Company set a $23.00 price objective on Arcus Biosciences and gave the stock an “equal weight” rating in a research note on Thursday, February 12th. HC Wainwright reiterated a “buy” rating and set a $32.00 price objective on shares of Arcus Biosciences in a research note on Monday, March 2nd. Leerink Partners set a $47.00 price objective on Arcus Biosciences in a research note on Monday, April 20th. Finally, Truist Financial upgraded Arcus Biosciences to a “strong-buy” rating in a research note on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.11.

Arcus Biosciences Stock Performance

Arcus Biosciences stock opened at $25.37 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.04 and a quick ratio of 4.04. The firm has a market capitalization of $3.19 billion, a P/E ratio of -7.98 and a beta of 0.87. The stock has a fifty day moving average price of $22.93 and a two-hundred day moving average price of $22.10. Arcus Biosciences, Inc. has a 52-week low of $7.91 and a 52-week high of $28.72.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Tuesday, May 5th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.10). Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The business had revenue of $17.00 million for the quarter, compared to the consensus estimate of $29.49 million. During the same quarter in the previous year, the company posted ($1.14) EPS. Arcus Biosciences’s revenue for the quarter was down 39.3% on a year-over-year basis. As a group, analysts anticipate that Arcus Biosciences, Inc. will post -3.55 EPS for the current fiscal year.

Trending Headlines about Arcus Biosciences

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Goldman Sachs raised its price target on Arcus Biosciences to $34 from $30 and maintained a buy rating, signaling greater confidence in upside potential.
• Positive Sentiment: HC Wainwright increased several earnings estimates for 2026, 2027, 2029 and 2030, including a higher FY2030 profit forecast, while keeping a buy rating and $32 target.
• Positive Sentiment: Arcus said PEAK-1 enrollment should be complete by year-end 2026 and that its cash runway extends into the second half of 2028, which may ease dilution worries. Article Title
• Neutral Sentiment: HC Wainwright did trim some longer-term estimates, including FY2026, FY2027 and FY2028 EPS, showing that the path to profitability remains challenging despite the higher targets.
• Neutral Sentiment: The company remains deeply unprofitable, and recent earnings results were weaker than expected, so investors are still watching for clinical and operating progress.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.